Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Glioblastoma: early-phase trial registry
29 of 63 indexed Recurrent Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 29 currently recruiting · #222 of 28,707 conditions by registered trial count
Recurrent Glioblastoma: 63 US clinical trials tracked, 29 recruiting.
Recurrent Glioblastoma is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition recurrent-glioblastoma
OPEN 29 | RECR 46% | LATE 2 | EARLY 54 | RANK #222 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Chronic Pain (46% recruiting · 302 trials)
Recurrent Glioblastoma lists 29 open slots (46% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Glioblastoma is recruiting above its size-band peers.
29 of 63 indexed trials (46%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Recurrent Glioblastoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 7 of 63 trials (11.1%). 39 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 63 trials that report a genuine target (sentinel values excluded). 54 of those (85.7%) plan for fewer than 100 participants.
-
Recurrent Glioblastoma research is mostly interventional.
61 interventional and 2 observational studies make up this index (96.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 1 of 2
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Jasper Gerritsen
NCT06283927
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
NCT06273176
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT06325683
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Academic and Community Cancer Research United
NCT06160206
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
University of Miami
NCT05284643
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Duke University
NCT06069726
Surgical Pembro +/- Olaparib w TMZ for rGBM
L. Nicolas Gonzalez Castro, MD, PhD
NCT05463848
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
NCT04003649
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Jonsson Comprehensive Cancer Center
NCT06090903
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Nicholas Butowski
NCT05557292
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
NCT03896568
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Boston Scientific Corporation
NCT05303467
Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT04559230
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT06058988
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT06344130
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
NCT06815029
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Ugonma Chukwueke
NCT06552260
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
NCT04590664
CARv3-TEAM-E T Cells in Glioblastoma
Marcela V. Maus, M.D.,Ph.D.
NCT05660369
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
University of Florida
NCT06558214
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Sabine Mueller, MD, PhD
NCT04323046
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Hideho Okada, MD, PhD
NCT06186401
CUE-102 in Recurrent Glioblastoma
David Reardon, MD
NCT06917885
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Abramson Cancer Center at Penn Medicine
NCT06613841
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
University of Pennsylvania
NCT07209241
Sonodynamic Therapy in Patients With Recurrent GBM
Shayan Moosa, MD
NCT06039709
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
Alpha Tau Medical
NCT06910306
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
Mayo Clinic
NCT07076472
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT05039281
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
CarThera
NCT05902169
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ECOG-ACRIN Cancer Research Group
NCT03115333
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT03749187
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT02974621
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
NCT04477200
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
NCT02208362
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
NCT05236036
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04729959
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT04528680
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Memorial Sloan Kettering Cancer Center
NCT04469075
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT04201873
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
M.D. Anderson Cancer Center
NCT00102648
Fimepinostat in Treating Brain Tumors in Children and Young Adults
Sabine Mueller, MD, PhD
NCT03893487
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
NCT04221503
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
University of Florida
NCT06389591
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
City of Hope Medical Center
NCT04214392
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT02192359
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT02337686
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Emory University
NCT05798507
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Emory University
NCT05091866
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
AstraZeneca
NCT00777153
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 17 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Glioblastoma page
63 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Recurrent Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Glioblastoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Glioblastoma condition card totals 63 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.